// App-Quantinova.ai

: Identifying super-responders to benralizumab in severe asthma

Researchers

Presenter

  • David J Jackson

Principal Investigators

  • Tim Harrison

  • Francesco Menzella

  • Vivian H Shih

  • Annie Burden

  • Esther Garcia Gil

Medical Centers

  • Nottingham Respiratory NIHR BRC, University of Nottingham; AstraZeneca, Nottingham; Cambridge, United Kingdom

  • AstraZeneca, Barcelona, Spain.

  • Astra Zeneca, Cambridge, United Kingdom

  • Guy's Severe Asthma Center, Guy’s & St. Thomas’ NHS Trust & Asthma UK Centre, School of Immunology & Microbial Sciences, King's College London, London, United Kingdom

  • AstraZeneca Gaithersburg, Gaithersburg, United States of America

  • Pneumology Unit, Azienda USL di Reggio Emilia-IRCCS, Reggio Emilia, Italy

Locations

  • United States

  • Italy

  • United Kingdom

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Benralizumab

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved